Tuberculosis Drug Market By Type of Tuberculosis (Active Tuberculosis and Latent Tuberculosis); By Treatment Type (First Line Drugs (Isoniazid, Rifampicin/ Rifampin, Ethambutol, Pyrazinamide, & Others), Second Line Drugs (Levofloxacin, Moxifloxacin, & Others)); By Route of Administration (Oral, Parenteral); By Dosage Form (Tablets, Capsules, Powder for Solution for Injection, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029

Report ID :AMI-867 | Category : Healthcare | Published Date : July, 2021 | Pages : 402 | Format :PDF